Data from the ARTS trial suggests Dutesteride may be beneficial in patients who have failed radical treatment for prostate cancer.

Data from the ARTS trial suggests Dutesteride may be beneficial in patients who have failed radical treatment for prostate cancer.

In an article by Schröder et al published in Europe Urol (2012) the authors show that Dutesteride can delay PSA rise in patients that have failed radical treatment for prostate cancer. The study, known as the ARTS trial, recruited 294 subjects that were randomised to either Dutesteride or placebo (147 in each treatment group). Only 187 (64%) completed 24 mo of treatment. In these patients Dutasteride significantly delayed the time to PSA doubling (p<0.001); the relative risk (RR) reduction was 66 % for the overall study period. Dutasteride also significantly delayed disease progression (p<0.001); the overall RR reduction in favour of dutasteride was 59%. The incidence of adverse events (AEs), serious AEs, and AEs leading to study withdrawal were similar between the treatment groups and in line with previously published data. A limitation of the study was that investigators were not blinded to PSA levels during the study.

Falling quality of human semen

In an article published in Human Reproduction (2012), the authors show that sperm concentration in semen of French men fell by 32% over a 17 year period. 26 609 partners of totally infertile women undergoing an assisted reproductive technology (ART) procedures in the whole of France were studied between 1989 and 2005. There was a continuous decline in concentration during this time.
This study adds to the debate about a global decrease in human sperm quality. Many small and sometimes methodologically flawed studies have reported similar temporal trends. There is growing biological, toxicological, experimental and human exposure data to support the endocrine disruptors’ hypothesis assuming that foetal exposure to endocrine disruptors could impair reproductive outcomes.

Contemporary American morbidity and mortality for radical cystectomy

Using a population-based cohort study of over 50,000 patients who underwent radical cystectomy in USA between 2001-2008, the authors report no change in complication or mortality rates over this time period. The study, which was published in BJUI (2012), reports that about 29% and 2% of patients undergoing RC will experience a postoperative complication or die during hospitalisation, respectively. Results were better for high volume centres that performed 25 or more cystectomies per year.

The combination of testosterone and sildenafil is no better at treating erectile dysfunction than sildenafil alone.

In a double blind placebo controlled trial published in Ann Intern Med (2012) the authors investigate whether men with both erectile dysfunction and low serum testosterone should add testosterone gel to their regular treatment with sildenafil. They report that the extra testosterone made no difference to erectile function scores or any other measure of sexual wellbeing in middle aged men, despite serum concentrations of testosterone increasing to within normal limits.